Chairman and Chief Executive Officer, Alkermes
Appears in 1 story
Leading combined company's sleep medicine expansion
Alkermes, a neuroscience-focused pharmaceutical company, completed its $2.37 billion acquisition of Avadel Pharmaceuticals on February 12, 2026, gaining immediate entry into the sleep medicine market. The deal adds LUMRYZ, the only once-nightly narcolepsy treatment, to Alkermes' portfolio alongside an emerging pipeline of orexin-based therapies that could address sleep disorders affecting millions of underdiagnosed patients.
Updated Feb 12
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
